A Phase 1/2 Study to Evaluate MEDI4736

Inclusion Criteria:

   - Age 18 or older.

   - In the dose-escalation phase: histologically- or cytologically- confirmed advanced
   solid tumor that is refractory to standard therapy and for which no standard therapy
   exists.

   - In the dose-expansion phase: histologically- or cytologically- confirmed advanced
   solid tumor where if an approved first-line therapy is available, participants must
   have failed, be intolerant to, be ineligible for, or have refused

   - Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.

   - Adequate organ and marrow function.

   - Participants must have at least 1 measurable lesion.

   - Available archived tumor tissue sample.

   - Willingness to provide consent for biopsy sample (dose-expansion only)

Exclusion Criteria:

   - Any prior Grade ≥ 3 immune-mediated adverse event (imAE) while receiving immunotherapy

   - Prior exposure to any anti-PD-1 or anti-PD-L1 antibody

   - Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
   treatment.

   - Prior treatment with immunotherapy agents including, but not limited to, tumor
   necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural
   killer (NK) cell inhibitors.

   - Active or prior documented autoimmune disease within the past 2 years

   - History of primary immunodeficiency

   - History of organ transplant that requires use of immunosuppressives

   - Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent
   treatment

   - Other invasive malignancy within 2 years

   - Women who are pregnant or lactating

   - Uncontrolled intercurrent illness

   - Known history of tuberculosis

   - Known to be human immunodeficiency virus (HIV) positive

   - Known to be Hepatitis B or C positive (except HCC participants)